New drug aims to curb brain injury after stroke

NCT ID NCT05970224

Completed Disease control Sponsor: Bioxodes S.A. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 24, 2026 · Updated 3 times

Summary

This study tests a drug called Ir-CPI in 23 people who have had a bleeding stroke (intracerebral hemorrhage). The drug is given once through a vein over 48 hours, alongside standard care. The goal is to see if it is safe and can reduce swelling and further brain damage around the bleed.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ir-CPI (a drug given as a single intravenous dose over 48 hours)
What this could lead to: If it works, this could point toward a treatment that limits brain damage after a hemorrhagic stroke.
What could go wrong: This is a very small, early-phase study (23 people) testing safety first. The drug may not reduce brain injury or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INTRACEREBRAL HEMORRHAGE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cerebrovascular disorder Inflammation intracerebral hemorrhage Intracranial Hemorrhages Neuroinflammatory Diseases stroke disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INTRACEREBRAL HEMORRHAGE

Contacts and locations

Locations

AZ Damiaan

Ostend, West Flanders, 8400, Belgium
AZ Sint-Jan

Bruges, West Flanders, 8000, Belgium
CHU Ambroise Paré

Mons, Hainaut, 7000, Belgium
Clinique CHC MontLégia

Liège, Belgium
UCL St Luc

Brussels, Belgium
UZ Brussel

Brussels, Belgium
UZ Gent

Ghent, East Flanders, 9000, Belgium
UZ Leuven

Leuven, Flemish Brabant, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.